Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$422.78 USD
+3.79 (0.90%)
Updated May 10, 2024 04:00 PM ET
After-Market: $422.80 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRTX 422.78 +3.79(0.90%)
Will VRTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
Other News for VRTX
Tweedy, Browne 2024 Client Letter
Alpine Immune ticks higher as HSR waiting period for Vertex Pharma deal expires
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
HHS panel to vote in Nov. on DMD screening for newborns